Biotech & Drug DiscoveryKONEX 1406108 approvals5 trials

Ensol Biosciences Inc.

Ensol Biosciences is a KONEX-listed biotech developing short peptide therapeutics that modulate protein-protein interactions (PPI).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded 2001, KONEX-listed 2018, Ensol Biosciences develops short peptides modulating protein-protein interactions. Pipeline: P2K (Peniel2000, disc disease), E1K (Engedi1000, knee osteoarthritis), C1K (Charis1000, cancer combo therapy), and approved pet drug JointVex. FY2025 revenue: KRW 25 million, all JointVex; P2K-DDD licensed to Yuhan and Spine Biopharma, FDA Phase 3.

Products & technology

용역서비스Synthesis/purification, component analysis (standardization), material separation/purification, peptide/compound/API synthesis, system-building and information analysis services
JointVex (EAD100)Companion-animal (dog) osteoarthritis treatment
P2K-DDD (Peniel2000)Degenerative disc disease (DDD) treatment
P2K indication expansion (P2K-IE)Expanded indications for P2K (other musculoskeletal diseases, fibrosis, tumors)
E1K (Engedi1000)Knee osteoarthritis (KOA) treatment

Regulatory approvals

data.go.kr · openFDA

7 Korean MFDS device approvals · 2020 / 1 US FDA 510(k) · 2024

FDAEnsol EnTM Specimen Collection and Transport System2024-08-29
510(k) · TraditionalMicrobiologyK220908
MFDSSpecimen transport media2020-08-26
Product approval · Class 1체외 제신 20-1277 호
MFDSSpecimen transport media2020-08-04
Product approval · Class 1체외 제신 20-1170 호
MFDSTool for specimens2020-07-24
Product approval · Class 1제신 20-1124 호
MFDSSpecimen transport media2020-07-01
Product approval · Class 1체외 제신 20-1014 호
MFDSSpecimen transport media2020-07-01
Product approval · Class 1체외 제신 20-1013 호
MFDSSpecimen transport media2020-07-01
Product approval · Class 1체외 제신 20-1012 호
MFDSSpecimen transport media2020-06-17
Product approval · Class 1체외 제신 20-882 호

Clinical trials

data.go.kr

5 MFDS clinical trial authorisations · 2018–2026 (Phase 1 2 · Phase 3 1 · Phase 2 1 · Phase 1b 1)

Phase 3엔게디1000(E1K)2026-01-22
3 trial sites
Phase 1카리스 1000 (C1K)2022-09-14
1 trial site
Phase 2엔게디1000(E1K)2022-01-28
9 trial sites
Phase 1b엔게디1000(E1K)2020-12-03
1 trial site
Phase 1엔게디 1000(Engedi 1000, E1K)2018-12-21
1 trial site

R&D and key agreements

Source: DART corporate disclosure

P2K(브니엘2000, Peniel2000) · 퇴행성디스크질환(DDD) · FDA 임상3상 진행 중(CSR 작성 중) · Out-licensed domestically to Yuhan and globally to Spine Biopharma (US)

P2K-IE · P2K 적응증 확대(근골격계질환, 섬유증, 종양) · 기술이전계약 체결(2024-07-04) · Licensing agreement with Spine Biopharma for expanded indications

E1K(엔게디1000) · 무릎 골관절염(KOA) · 국내 임상3상 진행 중(IND 승인) · Completed domestic Phase 1b and Phase 2 trials in Korea

C1K(카리스1000, Charis1000) · 항암제 병용치료 · 국내 임상1a상 완료

M1K · 알츠하이머병(AD) · 개발 중(후속 프로그램)

H1K · 비만(경구용) · 개발 중(후속 프로그램)

D1K · 항암(PDC) · 개발 중(후속 프로그램)

Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

BIONEERCORPORATION2 shared

Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.

Median Diagnostics Inc.2 shared

Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.

PCL. Inc2 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

RollingStone Co., Ltd.2 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

SD BIOSENSOR INC.2 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

Xcell Therapeutics Inc.2 shared

Xcell Therapeutics develops the domestically produced CellCor™ cell culture media series for cell and gene therapy manufacturing.

Aimed Bio Inc.1 shared

KOSDAQ-listed ADC oncology biotech that has out-licensed pipeline candidates to Biohaven, SK Plasma, and Boehringer Ingelheim.

CALTH. Inc1 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

Gencurix Inc.1 shared

Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.

NanoenTek,Inc.1 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

Precision Biosensor Inc.1 shared

KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.

Sources and updates

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
AI visibility: Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition